Abstract:Chemotherapy remains the mainstay of cancer treatment, and doxorubicin (DOX) is recommended as a first-line chemotherapy drug against cancer. However, systemic adverse drug reactions and multidrug resistance limit its clinical applications. Here, a tumor-specific reactive oxygen species (ROS) self-supply enhanced cascade responsive prodrug activation nanosystem (denoted as /L) was developed to optimize multidrug resistance tumor chemotherapy efficacy while minimizing the side effects. /L was constructed by encapsulating the ROS-generating agent β-lapachone (Lap) and the ROS-responsive doxorubicin prodrug (BDOX) in acidic pH-sensitive heterogeneous nanomicelles. /L exhibited particle size decrease and charge increase when it reached the tumor microenvironment due to acid-triggered PEG detachment, to favor its endocytosis efficiency and deep tumor penetration. Furthermore, after /L internalization, rapidly released Lap was catalyzed by the overexpressed quinone oxidoreductase-1 (NQO1) enzyme NAD(P)H in tumor cells to selectively raise intracellular ROS levels. Subsequently, ROS generation further promoted the specific cascade activation of the prodrug BDOX to exert the chemotherapy effects. Simultaneously, Lap-induced ATP depletion reduced drug efflux, synergizing with increased intracellular DOX concentrations to assist in overcoming multidrug resistance. This tumor microenvironment-triggered cascade responsive prodrug activation nanosystem potentiates antitumor effects with satisfactory biosafety, breaking the chemotherapy limitation of multidrug resistance and significantly improving therapy efficiency. Statement of significance Chemotherapy remains the mainstay of cancer treatment, and doxorubicin (DOX) is recommended as a first-line chemotherapy drug against cancer. However, systemic adverse drug reactions and multidrug resistance limit its clinical applications. Here, a tumor-specific reactive oxygen species (ROS) self-supply enhanced cascade responsive prodrug activation nanosystem (denoted as /L) was developed to optimize multidrug resistance tumor chemotherapy efficacy while minimizing the side effects. The work provides a new sight for simultaneously addressing the molecular mechanisms and physio-pathological disorders to overcome MDR in cancer treatment.

Tumor-Selective Cascade-Amplified Dual-Prodrugs Activation for Synergistic Oxidation-Chemotherapy

Time-programmed Activation of Dual Polyprodrugs for Synergistic Cascade Oxidation-Chemotherapy.

Self-boosting Stimulus Activation of a Polyprodrug with Cascade Amplification for Enhanced Antitumor Efficacy.

Prodrug-Based Nanoreactors with Tumor-Specific <i>In Situ</i> Activation for Multisynergistic Cancer Therapy

Dual-prodrug cascade activation for chemo/chemodynamic mutually beneficial combination cancer therapy

Self-immolative polyprodrug-based tumor-specific cascade amplificated drug release nanosystem for orchestrated synergistic cancer therapy

Prodrug-Based Nanoreactors with Tumor-Specific In Situ Activation for Multisynergistic Cancer Therapy

Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy

Cascade of reactive oxygen species generation by polyprodrug for combinational photodynamic therapy

Cyclic amplification of intracellular ROS boosts enzymatic prodrug activation for enhanced chemo-immunotherapy

ROS-Triggered Cycle Amplification Effect: A Prodrug Activation Nanoamplifier for Tumor-Specific Therapy.

Reactive Oxygen Species-Activated Self-Accelerated Drug Release Nanoparticles for Enhanced Cancer Combination Therapy

Acid-responsive Endosomolytic Polymeric Nanoparticles with Amplification of Intracellular Oxidative Stress for Prodrug Delivery and Activation.

A tumor-specific ROS self-supply enhanced cascade-responsive prodrug activation nanosystem for amplified chemotherapy against multidrug-resistant tumors

Theranostic Heterodimeric Prodrug with Dual‐Channel Fluorescence Turn‐On and Dual‐Prodrug Activation for Synergistic Cancer Therapy

A dual-amplified ROS-responsive nanosystem with self-accelerating drug release for synergistic chemotherapy.

A Tyrosinase-Responsive Tumor-Specific Cascade Amplification Drug Release System for Melanoma Therapy

A Self‐reinforced Activatable Photosensitizer Prodrug Enabling Synergistic Photodynamic and Chemotherapy

A Ph/ros Cascade‐Responsive Charge‐Reversal Nanosystem with Self‐Amplified Drug Release for Synergistic Oxidation‐Chemotherapy

Tumor-targeted supramolecular catalytic nanoreactor for synergistic chemo/chemodynamic therapy via oxidative stress amplification and cascaded Fenton reaction

Hypoxia Exacerbation-Triggered Doxorubicin Prodrug Activation for Sequential Photodynamic/Chemotherapy